- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04178174
구강인두암에 대한 정위 부스트 및 단기 방사선 요법 (SHORT-OPC)
HPV 관련 구인두암 임상시험을 위한 정위 부스트 및 단기 방사선 요법: 무작위 다심 2상 임상시험
This is a randomized clinical trial comparing the outcomes of short-course chemoradiation consisting in stereotactic boost to the gross tumor and de-esclalated chemoradiation to the elective neck in human papilloma associated oropharynx cancer vs. the current standard 7-week course chemoradiation.
연구 개요
상태
상세 설명
Concurrent platinum-based chemoradiation remains the standard of care in locally advanced head and neck cancer. The current standard radiation regimen consists in a 7-week course of conventionally fractionated radiotherapy to the gross tumor volume (GTV), along with bilateral prophylactic neck irradiation to an elective dose of ~ 50 Gy in 2 Gy per fraction. In addition to being cumbersome, the current protracted daily radiation course is associated with high rates of acute and late toxicities and significant deterioration of patients' quality of life. In the light of the remarkably improved prognosis of the distinct subgroup of HPV-OPC, there is growing interest for treatment de-intensification strategies in contemporaneous OPC cohorts.
Stereotactic ablative radiotherapy (SABR) allows for ultra-precise delivery of ablative radiation dose over a small number of fractions, by combining sharp dose gradients with use of optimal image guidance. The increased conformity and reduced margins used in SABR can substantially reduce the dose to surrounding organs at risk and could therefore reduce toxicity. In addition, previous work has shown that an elective dose of 40 Gy in 2 Gy per fraction, in conjunction with chemotherapy, is sufficient for microscopic sterilisation of cancer cells and can translate into a reduction of toxicities.
The goal of this trial is to compare the efficacy and safety of short-course chemoradiation consisting in stereotactic boost to the gross tumor of 14 Gy in 2 fractions followed by de-esclalated chemoradiation (40 Gy in 20 fractions and concurrent 2 cycles of Cisplatin 100mg/m2) in human papilloma associated oropharynx cancer vs. the current standard 7-week course chemoradiation (70 Gy in 33 fractions with 2-3 cycles of Cisplatin 100mg/m2).
This is an open label randomized phase III non inferiority trial. Patients will be randomized using a 1:1 ratio between the standard and the experimental arm and will be stratified by tumor stage and use of concurrent chemotherapy.
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Diane Trudel
- 전화번호: 514-890-8254
- 이메일: diane.dt.chum@ssss.gouv.qc.ca
연구 장소
-
-
Texas
-
Houston, Texas, 미국, 77030
- 모병
- University of Texas MD Anderson Cancer Center
-
연락하다:
- Troy Sneed
- 전화번호: (713) 794-5472
- 이메일: TSneed@mdanderson.org
-
수석 연구원:
- Jack Phan, MD PhD
-
-
-
-
British Columbia
-
Kelowna, British Columbia, 캐나다, V1Y 5L3
- 모병
- BC Cancer - Kelowna
-
연락하다:
- Jennifer Petterson
- 전화번호: 250-717-4272
- 이메일: jennifer.petterson@bccancer.bc.ca
-
-
Ontario
-
London, Ontario, 캐나다
- 모병
- London Health Sciences Center
-
연락하다:
- Karen Eddy
- 전화번호: (519) 685-8500
- 이메일: Karen.Eddy@lhsc.on.ca
-
-
Quebec
-
Montreal, Quebec, 캐나다, H2X 1R6
- 모병
- Centre Hospitalier de l'Université de Montréal
-
연락하다:
- Mom Phat
- 전화번호: 26906 514-890-8000
- 이메일: mom.phat.chum@ssss.gouv.qc.ca
-
수석 연구원:
- Houda Bahig
-
부수사관:
- Phuc-Félix Nguyen-Tan
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age ≥18 years
- Ability to provide written informed consent.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Biopsy proven diagnosis of squamous cell carcinoma of the oropharynx.
- Positive for HPV by p16 immunohistochemistry (IHC) or HPV in-situ hybridization (ISH)
- Clinical stage T1-3, N1 M0 (Stage I-II) as per AJCC 8th edition.
- Primary tumor < 30 cc
- Planned for curative chemoradiation
- For females of child-bearing age, a negative pregnancy test
Exclusion Criteria:
- Clinical N3 classification, as per AJCC 8th edition
- Clinically overt extranodal extension (ENE). As per AJCC 8th edition, clinically overt ENE is defined as invasion of the skin, infiltration of musculature/fixation to adjacent structures on clinical examination, cranial nerve, brachial plexus, sympathetic trunk or phrenic nerve invasion with dysfunction).
- Previous irradiation of the head and neck region
- Previous surgery of the HNC region (except for incisional or excisional biopsies)
- Pregnancy or breastfeeding
- Connective tissue disease
- Any medical condition that could, in the opinion of the investigator, prevent follow-up after radiotherapy.
- Non-Cisplatin concurrent chemotherapy
- Prior induction chemotherapy
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: SABR boost and de-escalated chemoradiation
SABR boost of 14 Gy in 2 fractions to the GTV, immediately followed by de-escalated chemoradiation. De-escalated chemoradiation will consist in 40 Gy in 20 fractions with concurrent high dose Cisplatin (3-weekly, 100 mg/m2) for 2 cycles, aiming for a cumulative dose of 200 mg/m2. |
Stereotactic body radiotherapy boost to the gross tumor volume to a dose of 14 Gy in 2 fractions, followed by cisplatin-based chemoradiation to a dose of 40 Gy in 20 fractions |
|
활성 비교기: Standard chemoradiation
The standard arm will consist of conventionally radiation to a dose of 70 Gy in 33 fractions concurrently with high dose Cisplatin (3-weekly, 100 mg/m2) for 2-3 cycles, aiming for a cumulative dose of ≥ 200 mg/m2. |
Standard Cisplatin-based chemoradiation to a dose of 70 Gy in 33 fractions |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression free survival
기간: 2 years after the end of chemoradiation
|
Patient alive with no local, regional or distant recurrence at 2 years after the end of chemoradiation |
2 years after the end of chemoradiation
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Subacute toxicity
기간: Between 2 and 6 months after the end of chemoradiation
|
Rate of grade ≥ 3 subacute toxicity |
Between 2 and 6 months after the end of chemoradiation
|
|
Acute toxicity
기간: Less than 2 months after the end of chemoradiation
|
Rate of grade ≥ 3 acute toxicity |
Less than 2 months after the end of chemoradiation
|
|
Late toxicity
기간: Between 6 months and 5-years after the end of chemoradiation
|
Rate of grade ≥ 3 late toxicity |
Between 6 months and 5-years after the end of chemoradiation
|
|
OS
기간: At 2- and 5-years after the end of chemoradiation
|
Overall survival |
At 2- and 5-years after the end of chemoradiation
|
|
locoregional control
기간: At 2- and 5-years after the end of chemoradiation
|
Patient alive with locoregional control |
At 2- and 5-years after the end of chemoradiation
|
|
Head and neck symptom burden
기간: At baseline, and 1-, 3-, 6-, 12- months post-treatment, and yearly from years 2-5 after the end of chemoradiation
|
Patient-reported head and neck symptom burden as measured by the MD Anderson Symptom Inventory Head and Neck Cancer Module. The core and head and neck cancer specific symptoms are rated on a 0-10 scale to indicate the presence and severity of the symptoms. Lower scores represent better functioning and quality of life. |
At baseline, and 1-, 3-, 6-, 12- months post-treatment, and yearly from years 2-5 after the end of chemoradiation
|
|
Dysphagia
기간: At baseline, and 1-, 3-, 6-, 12- months post-treatment, and yearly from years 2-5 after the end of chemoradiation
|
Patient-reported dysphagia as measured by the MD Anderson Dysphagia Index. Overall score ranges from 0 to 100, with higher score representing better functioning and quality of life. |
At baseline, and 1-, 3-, 6-, 12- months post-treatment, and yearly from years 2-5 after the end of chemoradiation
|
|
Time from treatment start to return to work
기간: Measured in days and reported at 2-years post-treatment
|
Time from first day of treatment start to first day of return to work. |
Measured in days and reported at 2-years post-treatment
|
공동 작업자 및 조사자
협력자
수사관
- 연구 의자: Phuc-Felix Nguyen-Tan, MD, Centre hospitalier de l'Université de Montréal (CHUM)
- 수석 연구원: Jack Phan, MD PhD, M.D. Anderson Cancer Center
- 수석 연구원: Khalil Sultanem, MD, Montreal Jewish General Hospital
- 연구 의자: Houda Bahig, MD PhD, Centre hospitalier de l'Université de Montréal (CHUM)
- 수석 연구원: David Palma, MD PhD, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .